Stockreport

ProKidney Reports Third Quarter 2025 Financial Results and Provides Regulatory and Clinical Updates [Yahoo! Finance]

ProKidney Corp. - Class A Ordinary Shares  (PROK) 
PDF More than half of the patients required for the Phase 3 REGEN-006 (PROACT 1) accelerated approval analysis using estimated glomerular filtration rate (eGFR) slope have [Read more]